ViaDerma Inc (VDRM)

[Mistral]

The downside is that Otiko can only manufacture 20k units of Viabecline under his NON-EXCLUSIVE license agreement with Howard Phillips. That fluff news release announcing 500k units is another lie to shareholders.

Phillips received a license from Keough for this same amount.

That's it. 20K units forever.

The shareholder communication with Keough and Phillips is linked below and available in the iBox.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129232062

Keough holds the Master Agreement. Read the Complaint and Contractual Exhibits to Complaint.

Don't underestimate the upside potential in this product, it will make millionaires of it's investors.

April 19, 2017 ViaDerma CEO Dr. Christopher Otiko presented a poster abstract of a study that showed Viabecline to be 96% effective in healing diabetic foot ulcers within 4 weeks. This is significant because a competing drug in recent Phase III Clinical trials did not meet the primary clinical endpoint of superiority versus placebo or which assessed the candidate in patients with mild infections of diabetic foot ulcers. The results of that clinical trial, which were also discussed extensively at DFCON, also showed that the competing drug did not show any meaningful difference in wound closure rate compared with vehicle, and neither trial met secondary endpoints of demonstrating a higher rate of eradication of bacteria for the drug vs the placebo. "These results are quite significant," said Otiko. "Viabecline has been well over 90% successful in treating diabetic foot infections. Our goal is to have Viabecline added to all diabetic foot ulcer treatment protocols which will save a lot of limbs and lives."